Home Cart Sign in  
Chemical Structure| 923032-37-5 Chemical Structure| 923032-37-5
Chemical Structure| 923032-37-5

Refametinib

CAS No.: 923032-37-5

Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50 values of 19 nM and 47 nM, respectively.

Synonyms: BAY 869766; RDEA119; BAY-69766

4.5 *For Research Use Only !

Cat. No.: A151521 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łËʶÊÊ Inquiry Inquiry
5mg łÍǶÊÊ Inquiry Inquiry
10mg łÿó¶ÊÊ Inquiry Inquiry
50mg łÇòò¶ÊÊ Inquiry Inquiry
100mg łËó˶ÊÊ Inquiry Inquiry
250mg łÍóʶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łËʶÊÊ

  • 5mg

    łÍǶÊÊ

  • 10mg

    łÿó¶ÊÊ

  • 50mg

    łÇòò¶ÊÊ

  • 100mg

    łËó˶ÊÊ

  • 250mg

    łÍóʶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Refametinib

CAS No. :923032-37-5
Formula : C19H20F3IN2O5S
M.W : 572.34
SMILES Code : O=S(C1(C[C@H](O)CO)CC1)(NC(C(NC(C(F)=C2)=CC=C2I)=C3F)=C(OC)C=C3F)=O
Synonyms :
BAY 869766; RDEA119; BAY-69766
MDL No. :MFCD18633256
InChI Key :RDSACQWTXKSHJT-NSHDSACASA-N
Pubchem ID :44182295

Safety of Refametinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Refametinib

MAPK

Isoform Comparison

Biological Activity

Target
  • MEK2

    MEK2, IC50:47 nM

  • MEK1

    MEK1, IC50:19 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
HCT116 1 μmol/L 6-9 months To investigate the mechanisms of resistance to the combination therapy of Cetuximab and Refametinib in KRAS-mutated colorectal cancer cell lines. PMC6350302
HCT15 1 μmol/L 6-9 months To investigate the mechanisms of resistance to the combination therapy of Cetuximab and Refametinib in KRAS-mutated colorectal cancer cell lines. PMC6350302
LOVO 1 μmol/L 6-9 months To investigate the mechanisms of resistance to the combination therapy of Cetuximab and Refametinib in KRAS-mutated colorectal cancer cell lines. PMC6350302
SW480 1 μmol/L 6-9 months To investigate the mechanisms of resistance to the combination therapy of Cetuximab and Refametinib in KRAS-mutated colorectal cancer cell lines. PMC6350302
LIM1215-HER2 0.05 to 10 μM 96 hours To evaluate the cell growth inhibiting effects of refametinib and pictilisib alone or in combination on HER2-amplified colon cancer cells. Results showed that the combined treatment with refametinib and pictilisib significantly inhibited the proliferation of LIM1215-HER2 and SW48-HER2 cells. PMC6549349
SW48-HER2 0.05 to 10 μM 96 hours To evaluate the cell growth inhibiting effects of refametinib and pictilisib alone or in combination on HER2-amplified colon cancer cells. Results showed that the combined treatment with refametinib and pictilisib significantly inhibited the proliferation of LIM1215-HER2 and SW48-HER2 cells. PMC6549349
HepG2 cells 33 nM 72 hours To evaluate the antiproliferative activity of BAY 86-9766 in HCC cell lines, results showed that BAY 86-9766 exhibited significant antiproliferative activity in HepG2 cells. PMC3819632
Hep3B cells 366 nM 72 hours To evaluate the antiproliferative activity of BAY 86-9766 in HCC cell lines, results showed that BAY 86-9766 exhibited significant antiproliferative activity in Hep3B cells. PMC3819632
PLC/PRF/5 cells 762 nM 72 hours To evaluate the antiproliferative activity of BAY 86-9766 in HCC cell lines, results showed that BAY 86-9766 exhibited significant antiproliferative activity in PLC/PRF/5 cells. PMC3819632
MH3924A cells 540 nM 72 hours To evaluate the antiproliferative activity of BAY 86-9766 in HCC cell lines, results showed that BAY 86-9766 exhibited significant antiproliferative activity in MH3924A cells. PMC3819632
Hepa129 cells 502 nM 72 hours To evaluate the antiproliferative activity of BAY 86-9766 in HCC cell lines, results showed that BAY 86-9766 exhibited significant antiproliferative activity in Hepa129 cells. PMC3819632
KRAS mutant CRC cells 1 μM 48 hours To investigate the effect of Refametinib on KRAS mutant CRC cells, it was found that Refametinib induced MIF secretion and activated STAT3 and MAPK pathways. PMC6068346
HCT116 and LOVO cells 1 μM 48 hours To investigate the effect of MIF siRNA on Refametinib sensitivity, it was found that MIF siRNA significantly reduced the viability of HCT116 and LOVO cells. PMC6068346
HepG2 cells 100 nM 1 hour Inhibited ERK1/2 phosphorylation and enhanced AZD8055-mediated inhibition of protein synthesis PMC8584319
ESO26 > 10 µM 5 days To investigate the anti-proliferative effect of Refametinib in ESO26 cells, the results showed that ESO26 cells were not sensitive to Refametinib and did not achieve IC50. PMC8088633
NCI-N87 > 10 µM 5 days To investigate the anti-proliferative effect of Refametinib in NCI-N87 cells, the results showed that NCI-N87 cells were not sensitive to Refametinib and did not achieve IC50. PMC8088633
OE19 2.75 ± 0.37 µM 5 days To investigate the anti-proliferative effect of Refametinib in OE19 cells, the results showed that OE19 cells were sensitive to Refametinib with an IC50 of 2.75 ± 0.37 µM. PMC8088633
SNU16 5.6 ± 1.4 µM 5 days To investigate the anti-proliferative effect of Refametinib in SNU16 cells, the results showed that SNU16 cells were sensitive to Refametinib with an IC50 of 5.6 ± 1.4 µM. PMC8088633
KATOIII 6.05 ± 0.84 µM 5 days To investigate the anti-proliferative effect of Refametinib in KATOIII cells, the results showed that KATOIII cells were sensitive to Refametinib with an IC50 of 6.05 ± 0.84 µM. PMC8088633
HEK293T cells 1 µM 1 hour Refametinib promoted the transition of the S218D/S222D double-mutant KinCon from an open conformation to a more closed kinase state, reflected by an increase in bioluminescence signals. PMC8065916
A2058 melanoma cells 1 µM 1 hour Refametinib treatment of A2058 cells triggered conformation dynamics of the MEK1 KinCon reporter, indicating a transition from an open to a closed kinase state. PMC8065916

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Nude mice LIM1215-HER2 and SW48-HER2 tumor xenograft models Oral ceritinib 30 mg/kg, AZD1208 15 mg/kg daily for 14 days To evaluate the antitumor activity of refametinib alone or in combination with pictilisib in HER2-amplified colon cancer xenograft models. Results showed that the combined treatment with refametinib and pictilisib almost completely suppressed the growth of LIM1215-HER2 and SW48-HER2 tumors. PMC6549349
mice Hep3B xenograft model oral 100 mg/kg once daily for 14 days To evaluate the antitumor activity of BAY 86-9766 monotherapy in the Hep3B xenograft model, results showed that BAY 86-9766 significantly prolonged the survival of mice. PMC3819632
Mice Lewis Lung Carcinoma model Oral 0.5 g/kg or 1.0 g/kg diet 62 weeks To evaluate the effect of Refametinib on tumor ανβ3 expression, results showed that ανβ3 signal in treated mice was significantly lower than in non-treated mice at 1 and 2 weeks PMC5157790

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00610194 Advanced Cancer PHASE1 COMPLETED 2012-08-01 TGen Clinical Research Service... More >>s at Scottsdale Healthcare, Scottsdale, Arizona, 85258, United States|UCHSC, Aurora, Colorado, 80045, United States|Roswell Park Cancer, Buffalo, New York, 14263, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.74mL

1.75mL

0.87mL

17.47mL

3.49mL

1.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories